Randomized Controlled Double-Blind-Study of Role of Recombinant Erythropoietin in the Prevention of Chronic Lung-Disease

INTERVENTION: Infants were randomly allocated and received either R‐HuEpo (480 U/kg/wk) or placebo (4% human serum albumin) by twice weekly subcutaneous injection. CONDITION: Neonatal diseases ; Neonatal Diseases PRIMARY OUTCOME: Number of days on respiratory support SECONDARY OUTCOME: Number of blood transfusions required INCLUSION CRITERIA: 1. Gestational age <32 weeks and/or birthweight <1500 g 2. Requirement for mechanical ventilation and/or supplemental oxygen at birth 3. No severe renal, hepatic or coagulation disorders or major congenital malformation 4. Still require mechanical ventilation/oxygen on day 7‐14 after birth